| Literature DB >> 23721463 |
Nina Deng1, Jeroan J Allison, Hua Julia Fang, Arlene S Ash, John E Ware.
Abstract
BACKGROUND: Relative validity (RV), a ratio of ANOVA F-statistics, is often used to compare the validity of patient-reported outcome (PRO) measures. We used the bootstrap to establish the statistical significance of the RV and to identify key factors affecting its significance.Entities:
Mesh:
Year: 2013 PMID: 23721463 PMCID: PMC3681626 DOI: 10.1186/1477-7525-11-89
Source DB: PubMed Journal: Health Qual Life Outcomes ISSN: 1477-7525 Impact factor: 3.186
ANOVA-based F-statistic and relative validity for CKD-specific and generic PRO measures across clinically-defined groups (N = 453)
| | | | | | | | | | | | | | |
| QDIS-CKD | | | | | | | | | | | | | |
| CAT-5 | 39.83 | (22.17) | 1 | 16.19 | (21.51) | 1 | 19.25 | (21.63) | 1 | 1 | 57.43** | 1 | - |
| Static-6 | 39.18 | (22.86) | 0.91 | 16.86 | (21.84) | 0.96 | 19.60 | (21.29) | 0.93 | 0.94 | 50.15** | 0.87 | (0.72-1.03) |
| Static-34 | 35.93 | (21.23) | 0.93 | 14.90 | (20.05) | 0.96 | 18.71 | (20.52) | 0.95 | 0.95 | 48.01** | 0.84 | (0.71-0.97) |
| KDQOL | | | | | | | | | | | | | |
| Burden | 48.83 | (26.81) | -0.60 | 76.62 | (24.76) | -0.73 | 68.21 | (28.90) | -0.77 | -0.74 | 44.46** | 0.77 | (0.53-1.09) |
| Symptoms | 71.95 | (16.23) | -0.57 | 80.58 | (15.80) | -0.65 | 80.03 | (15.96) | -0.66 | -0.65 | 15.11** | 0.26 | (0.13-0.44) |
| Effects | 63.41 | (21.92) | -0.54 | 84.38 | (17.59) | -0.79 | 77.86 | (20.18) | -0.73 | -0.71 | 43.95** | 0.77 | (0.52-1.10) |
| | | | | | | | | | | | | | |
| SF-12 | | | | | | | | | | | | | |
| PF | 37.06 | (10.75) | -0.52 | 45.38 | (11.12) | -0.57 | 44.88 | (10.69) | -0.65 | -0.63 | 31.12** | 0.54 | (0.32-0.85) |
| RP | 38.00 | (9.41) | -0.65 | 45.12 | (9.78) | -0.61 | 45.83 | (9.91) | -0.63 | -0.69 | 34.12** | 0.59 | (0.38-0.89) |
| BP | 43.19 | (11.67) | -0.47 | 46.71 | (11.27) | -0.53 | 47.10 | (11.66) | -0.49 | -0.50 | 5.84** | 0.10 | (0.02-0.22) |
| GH | 39.08 | (11.19) | -0.47 | 41.99 | (10.11) | -0.51 | 43.71 | (10.93) | -0.56 | -0.52 | 7.79** | 0.14 | (0.04-0.28) |
| VT | 45.72 | (9.25) | -0.44 | 46.40 | (10.15) | -0.46 | 48.35 | (9.93) | -0.48 | -0.44 | 3.04* | 0.05 | (0.00-0.15) |
| SF | 42.75 | (11.79) | -0.65 | 47.81 | (11.25) | -0.61 | 47.83 | (10.78) | -0.60 | -0.64 | 11.02** | 0.19 | (0.07-0.34) |
| RE | 44.59 | (11.64) | -0.52 | 48.39 | (10.05) | -0.49 | 48.39 | (9.76) | -0.42 | -0.51 | 7.01** | 0.12 | (0.03-0.25) |
| PCS | 36.60 | (10.29) | -0.54 | 43.49 | (10.37) | -0.56 | 44.08 | (10.72) | -0.66 | -0.64 | 26.61** | 0.46 | (0.27-0.74) |
| MCSd | 49.74 | (10.38) | -0.49 | 50.42 | (9.57) | -0.45 | 50.55 | (9.94) | -0.32 | -0.40 | 0.32 | - | - |
| MHd | 49.85 | (10.39) | -0.43 | 50.71 | (10.25) | -0.49 | 50.31 | (9.95) | -0.33 | -0.38 | 0.26 | - | - |
*Significant at the 0.05 level ** Significant at the 0.01 level.
Abbreviations: ANOVA analysis of variance, RV relative validity, CKD chronic kidney disease, PRO patient-reported outcome, QDIS-CKD quality-of-life disease impact scale for chronic kidney disease, KDQOL kidney disease quality-of-life, SF-12 Short Form 12, PF physical functioning, RP role physical, BP bodily pain, GH general health, VT vitality, SF social functioning, RE role emotional, PCS physical component summary, MCS mental component summary, MH mental health.
ar refers to the correlation of scores between each comparison measure and the reference measure (QDIS-CKD CAT-5) within each clinical group.
br(total) refers to the correlation of scores between each comparison measure and the reference measure (QDIS-CKD CAT-5) for the total group (N = 453).
c The 95% confidence interval of the RV was derived from the original data using the bootstrap BCa interval.
d The F-statistics for SF-12 MCS and MH are small and non-significant ( p-values of 0.73 and 0.77 separately), therefore their RVs were not computed and excluded from significance test.
Figure 1Bootstrap standard error of the RV by sample size, denominator F-statistic, and correlation between measures. Factors not varied in simulation were held constant as in Table 1. The RVs were held constant in simulations and are parenthesized next to the measures in the legend. Abbreviations: RV, relative validity; QDIS, quality-of-life disease impact scale; KDQOL, kidney disease quality-of-life; SF-12, Short Form 12; PF, physical functioning; RP, role physical; BP, bodily pain; GH, general health; VT, vitality; SF, social functioning; RE, role emotional; PCS, physical component summary.
Figure 2Bootstrap confidence interval for the RV of SF-12 RP by sample size, denominator F-statistic, and correlation. The vertical bars present the confidence intervals with upper and lower bounds. The dots on the vertical bars represent the point estimates of RVs. Abbreviations: RV, relative validity; SF-12, Short Form 12; RP, role physical.
Figure 3Power of the RV by sample size, denominator F-statistic, and correlation between measures. Power was calculated as the probability of obtaining a statistically significant RV from simulations. Factors not varied in simulation were held constant as in Table 1. The RVs were held constant in simulations and are parenthesized next to the measures in the legend. Abbreviations: RV, relative validity; QDIS, quality-of-life disease impact scale; KDQOL, kidney disease quality-of-life; SF-12, Short Form 12; PF, physical functioning; RP, role physical; BP, bodily pain; GH, general health; VT, vitality; SF, social functioning; RE, role emotional; PCS, physical component summary.
Figure 4Histogram of simulated RV estimates for SF-12 RP by denominator F-statistic. The SF-12 RP had RV = 0.59. The sample size and correlation with the reference measure were fixed at the values observed in the original data. Abbreviations: RV, relative validity; SF-12, Short Form 12; RP, role physical.
Figure 5Bootstrap confidence intervals for RVs of SF-12 RP, KDQOL Burden, and QDIS-CKD Static-34 by number of bootstrap replicates. The sample size, denominator F-statistic, and correlation with reference measure were fixed as in Table 1. The vertical bars present the confidence intervals with upper and lower bounds. The dots on the vertical bars represent the point estimates of RVs. Abbreviations: RV, relative validity; SF-12, Short Form 12; RP, role physical; KDQOL, kidney disease quality-of-life; QDIS, quality-of-life disease impact scale; CKD, chronic kidney disease.